Literature DB >> 30306863

Recent Advances in Glyoxalase-I Inhibition.

Qosay A Al-Balas1, Mohammad A Hassan1, Nizar A Al-Shar'i1, Ghazi A Al Jabal1, Ammar M Almaaytah2.   

Abstract

Glyoxalase system is a ubiquitous system in human cells which has been examined thoroughly for its role in different disease conditions. It is composed of Glyoxalase-I (Glo-I) and Glyoxalase- II which perform an essential metabolic process inside the cell by detoxifying endogenous harmful metabolites, mainly methylglyoxal (MG) into non-toxic D-lactic acid. Tumor cells are well-known for their high metabolic rate which results in elevated levels of toxic metabolites. The over-expression of Glo-I in tumor cells makes this enzyme a pivotal target for anticancer drug development. Glo-I is metalloenzyme with two polypeptide chains and encompasses two active sites with an integral zinc atoms at their center. This review aims to highlight the important role of Glo-I in different pathogenic conditions, and more importantly, it provides a thorough discussion of all known human Glo-I inhibitors since its discovery, a hundred years ago, up to date. It embraces the different classes they belong to, their design and chemical structures. We believe this review will help guide the design of novel and potent human Glo-I inhibitors by providing a handy reference for interested researchers in this target. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  GSH; Human glyoxalase-I; inhibitors; metalloenzyme; pathogenesis; zinc-binding.

Mesh:

Substances:

Year:  2019        PMID: 30306863     DOI: 10.2174/1389557518666181009141231

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN: 1389-5575            Impact factor:   3.862


  6 in total

1.  Metal-Binding Pharmacophore Library Yields the Discovery of a Glyoxalase 1 Inhibitor.

Authors:  Christian Perez; Amanda M Barkley-Levenson; Benjamin L Dick; Peter F Glatt; Yadira Martinez; Dionicio Siegel; Jeremiah D Momper; Abraham A Palmer; Seth M Cohen
Journal:  J Med Chem       Date:  2019-01-31       Impact factor: 7.446

2.  Discovery of a nanomolar inhibitor of the human glyoxalase-I enzyme using structure-based poly-pharmacophore modelling and molecular docking.

Authors:  Nizar A Al-Shar'i; Qosay A Al-Balas; Rand A Al-Waqfi; Mohammad A Hassan; Amer E Alkhalifa; Nehad M Ayoub
Journal:  J Comput Aided Mol Des       Date:  2019-10-19       Impact factor: 3.686

3.  Methylglyoxal Acts as a Tumor-Promoting Factor in Anaplastic Thyroid Cancer.

Authors:  Cinzia Antognelli; Sonia Moretti; Roberta Frosini; Efisio Puxeddu; Angelo Sidoni; Vincenzo N Talesa
Journal:  Cells       Date:  2019-06-06       Impact factor: 6.600

Review 4.  Maternal malnutrition and anaemia in India: dysregulations leading to the 'thin-fat' phenotype in newborns.

Authors:  Prachi Pandit; Sanjeev Galande; François Iris
Journal:  J Nutr Sci       Date:  2021-10-11

5.  Evaluation of Fructosamine 3-kinase and Glyoxalase 1 activity in normal and breast cancer tissues.

Authors:  Tooba Yousefi; Abdol Rahim Gholizadeh Pasha; Ghodsieh Kamrani; Ailin Ebrahimzadeh; Ali Zahedian; Karimollah Hajian-Tilaki; Mohammad Aghajani; Durdi Qujeq
Journal:  Biomedicine (Taipei)       Date:  2021-09-01

6.  Design, Synthesis and Biological Evaluation of 1,4-Benzenesulfonamide Derivatives as Glyoxalase I Inhibitors.

Authors:  Suaad Abdallah Audat; Qosay Ali Al-Balas; Buthina Abdallah Al-Oudat; Mo'ad Jamil Athamneh; Amanda Bryant-Friedrich
Journal:  Drug Des Devel Ther       Date:  2022-03-28       Impact factor: 4.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.